Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
USPTO mass resignation concerns; INPI president interview; WTR summit speaker line-up; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...
Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...
The S&P 500 and Nasdaq ended higher with boosts from gains in Nvidia and Eli Lilly, while the Dow dipped slightly after a ...
The drugmaker's shares were up nearly 5% at $882 in afternoon trading. The stock has more than doubled in value in the last two years, making it the most valuable healthcare company in the world, but ...
Major Wall Street indexes saw slight gains on Thursday as strong earnings reports from companies like Eli Lilly, Tapestry, ...
Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback